Modalis Therapeutics Corporation
4883株式会社モダリス
Latest half-year results
First half · fiscal year to 2026-12 · filed 2026-08-14For the first half of the fiscal year to 2026-12: Ordinary income ¥-1 billion, Net income ¥-0.9 billion.
| This period | Year on year | |
|---|---|---|
| Ordinary profit | −¥955m | — |
| Net profit to owners | −¥910m | — |
From the securities report on EDINET, which states no forecast. History via /v1/companies/4883/earnings-releases.
Financials
Japan GAAP · consolidated · fiscal year to 2025-12-31- Revenue
- —
- Net income
- −¥2.2bn
- ROE
- —
- Equity ratio
- 93.0%
- Dividend / share
- —
- Employees
- 17
| Fiscal year | Revenue | Net income | Total assets | Net assets | ROE | EPS | Operating CF |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | — | −¥2,153m | ¥2,964m | ¥2,793m | — | ¥-27.86 | −¥2,118m |
| 2024-12-31 | — | −¥1,318m | ¥3,692m | ¥3,548m | — | ¥-28.57 | −¥1,432m |
| 2023-12-31 | — | −¥2,392m | ¥2,026m | ¥1,380m | — | ¥-77.24 | −¥2,254m |
| 2022-12-31 | ¥41m | −¥2,703m | ¥3,130m | ¥2,941m | — | ¥-92.85 | −¥1,896m |
| 2021-12-31 | ¥1m | −¥739m | ¥6,069m | ¥5,549m | — | ¥-25.7 | −¥747m |
Indicators
Computed by us from filings · fiscal year to 2025-12-31| Metric | Value | Percentile among listed companies |
|---|---|---|
| ROE, % | — | — |
| Ordinary margin | — | — |
| Equity ratio, % | 93 | 99.5 |
| Revenue growth | — | — |
| Net income growth | -0.6334 | 10.9 |
| Operating cash flow / assets | -0.7147 | 0.3 |
Via /v1/companies/4883/indicators. Descriptive figures, not a rating and not investment advice.
From other filings
As the company states themSegments, votes and tender offers
Stated in EDINET filings/v1/companies/4883/votingOwnership changes
All companies →- 2026-10-27
Evo Fund reduced holdings in Modalis Therapeutics Corporation (4883) to 6.71% from 7.61%.
- 2026-10-22
Evo Fund reduced holdings in Modalis Therapeutics Corporation (4883) to 7.61% from 8.96%.
- 2026-09-28
Evo Fund reduced holdings in Modalis Therapeutics Corporation (4883) to 8.96% from 9.02%.
- 2026-09-18
Evo Fund reduced holdings in Modalis Therapeutics Corporation (4883) to 9.02% from 10.28%.
- 2026-09-18
Holdings of Evo Fund in Modalis Therapeutics Corporation (4883) moved below 10% (10.28% -> 9.02%).
- 2026-09-17
Evo Fund reduced holdings in Modalis Therapeutics Corporation (4883) to 10.28% from 14.23%.
- 2026-09-07
Evo Fund reduced holdings in Modalis Therapeutics Corporation (4883) to 14.23% from 15.16%.
- 2026-08-18
Evo Fund reduced holdings in Modalis Therapeutics Corporation (4883) to 15.16% from 16.20%.
- 2026-07-30
Evo Fund reduced holdings in Modalis Therapeutics Corporation (4883) to 16.20% from 17.46%.
- 2026-07-21
Evo Fund reduced holdings in Modalis Therapeutics Corporation (4883) to 17.46% from 19.07%.
Trades by 5% holders
From the 60-day trade tables in 5% reports| Holder | Period | Net shares | Net % of shares | Avg. filed price | Range |
|---|---|---|---|---|---|
| Evo Fund | 2023-11-07 – 2026-10-20 | +4,125,312 | +1.94pt | ¥72.63 | ¥29–139 |
| Evolution Capital Management LLC | 2023-11-07 – 2026-10-20 | +4,125,112 | +1.94pt | ¥72.63 | ¥29–139 |
| individual filer | 2025-04-30 – 2025-04-30 | +1,200 | 0.00pt | — | — |
| 株式会社SBI証券 | 2021-10-03 – 2025-01-23 | -63 | +0.06pt | ¥89.27 | ¥69–559 |
| SBIインベストメント株式会社 | 2024-12-10 – 2024-12-17 | -700,000 | −1.02pt | — | — |
| individual filer | 2022-02-15 – 2024-09-17 | -1,082,600 | −3.38pt | — | — |
| NOMURA INTERNATIONAL PLC | 2022-10-11 – 2023-09-27 | -188,038 | −0.64pt | ¥238.49 | ¥134–428 |
| 野村證券株式会社 | 2022-10-19 – 2023-09-27 | +220,000 | −0.43pt | ¥320.24 | ¥162–347 |
Net shares and the average are our calculations. Prices are filed prices as stated by the filer, mostly for off-market trades; they are not market prices. Stock lending, custody transfers and option exercises are excluded from net shares. Every row via /v1/companies/4883/trades.
5% filings
Large shareholding reports on 4883| Filed | Filer | Stake | Change | Stated purpose |
|---|---|---|---|---|
| 2026-10-27 | Evo Fund | 6.71% | −0.90pt | pure investment |
| 2026-10-22 | Evo Fund | 7.61% | −1.35pt | pure investment |
| 2026-09-28 | Evo Fund | 8.96% | −0.06pt | pure investment |
| 2026-09-18 | Evo Fund | 9.02% | −1.26pt | pure investment |
| 2026-09-17 | Evo Fund | 10.28% | −3.95pt | pure investment |
| 2026-09-07 | Evo Fund | 14.23% | −0.93pt | pure investment |
| 2026-08-18 | Evo Fund | 15.16% | −1.04pt | pure investment |
| 2026-07-30 | Evo Fund | 16.20% | −1.26pt | pure investment |
| 2026-07-21 | Evo Fund | 17.46% | −1.61pt | pure investment |
| 2026-07-13 | Evo Fund | 19.07% | −1.12pt | pure investment |
Major shareholders
As of fiscal year end 2025-12-31| Shareholder | Shares | Ratio |
|---|---|---|
| 株式会社LSIM | 2,831,800 | 3.27% |
| 楽天証券株式会社共有口 | 2,664,500 | 3.07% |
| 株式会社SBI証券 | 2,474,744 | 2.86% |
| individual holder | 2,340,000 | 2.70% |
| individual holder | 1,800,000 | 2.08% |
| individual holder | 1,581,300 | 1.82% |
| STATE STREET BANK AND TRUST COMPANY | 1,000,000 | 1.15% |
| マネックス証券株式会社 | 723,277 | 0.83% |
| 松井証券株式会社 | 650,300 | 0.75% |
| 株式会社証券ジャパン | 615,300 | 0.71% |
Get this as JSON
GET /v1/companies/4883
GET /v1/companies/4883/financials
GET /v1/companies/4883/details
GET /v1/companies/4883/segments
GET /v1/companies/4883/voting
GET /v1/companies/4883/tender-offers
GET /v1/companies/4883/indicators
GET /v1/companies/4883/earnings-releases
GET /v1/events?ticker=4883
GET /v1/companies/4883/trades
GET /v1/companies/4883/cross-holdings
GET /v1/companies/4883/brief